CHDI conference session V - clinical updates from Uniqure AMT-130 program

CHDI conference session V - clinical updates from Uniqure AMT-130 program

David Cooper David Cooper from Uniqure spoke about the current status and future plan for the first gene therapy trial for HD involving an AAV5 expressing a microRNA targeting HTT human exon-1 sequences, termed AMT-130. David described the preclinical work conducted to support the clinical trial data, in work that…
2021 Course on targeting mutant HTT therapeutically for clinicians of the movement disorder society (MDS) by Ignacio Munoz-Sanjuan

2021 Course on targeting mutant HTT therapeutically for clinicians of the movement disorder society (MDS) by Ignacio Munoz-Sanjuan

In this 2021 course, Dr. Ignacio Munoz-Sanjuan, VP of translational biology at CHDI Foundation, speaks to the clinicians and movement disorder residents as part of a course about Huntington’s disease organized by EHDN and MDS. The seminar focuses on our current understanding of HTT biological aspects relevant to the development…
en_USEnglish